Physician Survey on Monitoring of Patients Treated With Quetiapine

AstraZeneca800 enrolled

Overview

A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials

Assessment of physician behavior regarding metabolic monitoring of patients treated with SEROQUEL® (quetiapine fumarate) Tablets and SEROQUEL® (quetiapine fumarate) Extended Release Tablets in selected countries in the EU

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

Schizophrenia Bipolar Disorder Major Depressive Disorder

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Physicians targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. Exclusion Criteria: * Physicians who have participated in a survey involving SEROQUEL® / SEROQUEL® XR in the past six months are not eligible to participate in this survey.

Outcomes

Primary Outcomes

Determination via survey whether physicians or someone in their practice perform monitoring of patients treated with Seroquel or Seroquel XR for metabolic issues related to treatment; refer their patients to another physician for monitoring.

Time frame: Over 6- 8 weeks.

Determination via survey whether physicians monitor tests for hyperlipidemia in patients who are taking Seroquel or Seroquel XR.

Time frame: Over 6- 8 weeks.

Determination via survey whether physicians monitor for signs and symptoms of hyperglycemia in patients who are taking Seroquel or Seroquel XR.

Time frame: Over 6- 8 weeks.

Determination via survey whether physicians monitor blood glucose in patients with diabetes or monitor patients with risk factors for diabetes for worsening of glycemic control if they are taking Seroquel or Seroquel XR.

Time frame: Over 6- 8 weeks.

Determination via survey whether physicians monitor weight at initiation of treatment with Seroquel or Seoquel XR and on a regular basis after initiating treatment.

Time frame: Over 6- 8 weeks.

Secondary Outcomes

Determination via survey whether physicians counsel patients taking with Seroquel or Seroquel XR on healthy eating, exercise, and healthy lifestyle improvements.

Time frame: Over 6- 8 weeks.

Determination via survey whether physicians received educational information relevant to the issues in the survey from AstraZeneca.

Time frame: Over 6- 8 weeks.

Determination via survey whether physicians read the educational information.

Time frame: Over 6- 8 weeks.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.